Comparison of l-type amino acid transporter 1 expression and l-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer

Nuclear Medicine and Biology

Volumn 37, Issue 8, 2010, Pages 911-916

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Shimizu, Kimihiro ^a   Imai, Hisao ^a   Tominaga, Hideyuki ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Hisada, Takeshi ^a   Ishizuka, Tamotsu ^a   Kanai, Yoshikatsu ^b   Oyama, Tetsunari ^a   Mori, Masatomo ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Fluorine 18 methyltyrosine; LAT1; NSCLC; Positron emission tomography; Prognostic factor

Indexed keywords

3 ALPHA METHYLTYROSINE F 18; AMINO ACID TRANSPORTER; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG TUMOR LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ISOTOPE TRACING; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE STUDY; REFERENCE VALUE; SCORING SYSTEM; SEX DIFFERENCE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LUNG NEOPLASMS; MALE; METHYLTYROSINES; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 78049484287     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.06.004     Document Type: Article

References (29)

1. Christensen H.N. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990, 70:43-77.
2. McGivan J.D., Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994, 299:321-334.
3. Oxender D.L., Christensen H.N. Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 1963, 197:765-767.
4. Kanai Y., Segawa H., Miyamoto K., Uchino H., Takeda E., Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998, 273:23629-23632.
5. Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T., et al. Human l-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001, 1514:291-302.
6. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. Prognostic significance of l-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008, 98:742-748.
7. Takeuchi K., Ogata S., Nakanishi K., Ozeki Y., Hiroi S., Tominaga S., et al. LAT1 expression in non-small-cell lung carcinomas: analysis by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases). Lung Cancer 2010, 68:58-65.
8. Tomiyoshi K., Amed K., Muhammad S., Higuchi T., Inoue T., Endo K., et al. Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: l-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun 1997, 18:169-175.
9. 18F α-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med 1999, 40:399-405.
10. Watanabe H., Inoue T., Shinozaki T., Yanagawa T., Ahmed A.R., Tomiyoshi K., et al. PET imaging of musculoskeletal tumors with fluorine-18 α-methyl tyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000, 27:1509-1517.
11. Inoue T., Koyama K., Oriuchi N., Alyafei S., Yuan Z., Suzuki H., et al. Detection of malignant tumors: whole-body PET with fluorine-18-α-methyl tyrosine versus FDG-preliminary study. Radiology 2001, 220:54-62.
12. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007, 131:1019-1027.
13. Kaira K., Oriuchi N., Otani Y., Shimizu K., Tanaka S., Imai H., et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007, 13:6369-6378.
14. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 2009, 50:1770-1776.
15. Mountain C.F. Revision in the International System for Staging Lung Cancer. Chest 1997, 11:1710-1717.
16. Oriuchi N., Tomiyoshi K., Inoue T., Ahmed K., Sarwar M., Tokunaga M., et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 1996, 37:457-462.
17. Zhang H., Inoue T., Alyafei S., Tian M., Oriuchi N., Ichikawa A., et al. Fundamental study of hot spot detectability in 3-dimensional positron emission tomography. Ann Nucl Med 2000, 14:279-284.
18. Inoue T., Oriuchi N., Kunio M., Tomiyoshi K., Tomaru Y., Aoyagi K., et al. Accuracy of standardized uptake value (SUV) measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999, 20:849-857.
19. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009, 66:120-126.
20. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009, 100:249-254.
21. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. CD98 expression is associated with poor prognosis in resected non-small cell lung cancer with lymph node metastasis. Ann Surg Oncol 2009, 16:3473-3481.
22. Imai H., Kaira K., Oriuchi N., Yanagitani N., Sunaga N., Ishizuka T., et al. l-Type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 2009, 54:804-813.
23. Ohkame H., Masuda H., Ishii Y., Kanai Y. Expression of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 2001, 78:265-271. [discussion 271--2].
24. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. l-Type amino acid transporter 1 (LAT1) and CD98 expression in the primary site and the metastatic site of human neoplasms. Cancer Sci 2008, 99:3280-3286.
25. 18F-FDG PET-CT: a clinicopathological study. Int J Cancer 2008, 124:1152-1160.
26. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. Expression of l-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008, 204:553-561.
27. Kaira K., Oriuchi N., Imai H., Shimizu K., Yanagitani N., Sunaga N., et al. l-Type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 2009, 99:433-438.
28. 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 2009, 100:753-758.
29. Oriuchi N., Higuchi T., Ishikita T., Miyakubo M., Hanaoka H., Iida Y., et al. Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 2006, 97:1291-1297.